<?xml version='1.0' encoding='utf-8'?>
<document id="30587933"><sentence text="Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects."><entity charOffset="49-67" id="DDI-PubMed.30587933.s1.e0" text="berberine chloride" /><entity charOffset="73-84" id="DDI-PubMed.30587933.s1.e1" text="simvastatin" /><entity charOffset="89-100" id="DDI-PubMed.30587933.s1.e2" text="fenofibrate" /><pair ddi="false" e1="DDI-PubMed.30587933.s1.e0" e2="DDI-PubMed.30587933.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30587933.s1.e0" e2="DDI-PubMed.30587933.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s1.e0" e2="DDI-PubMed.30587933.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s1.e1" e2="DDI-PubMed.30587933.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s1.e1" e2="DDI-PubMed.30587933.s1.e2" /></sentence><sentence text="Fenofibrate (Fbt) is a prodrug that has been used to reduce low-density-lipoprotein cholesterol, triglycerides, and increase high-density-lipoprotein cholesterol"><entity charOffset="0-11" id="DDI-PubMed.30587933.s2.e0" text="Fenofibrate" /><entity charOffset="13-16" id="DDI-PubMed.30587933.s2.e1" text="Fbt" /><entity charOffset="84-95" id="DDI-PubMed.30587933.s2.e2" text="cholesterol" /><entity charOffset="97-110" id="DDI-PubMed.30587933.s2.e3" text="triglycerides" /><entity charOffset="150-161" id="DDI-PubMed.30587933.s2.e4" text="cholesterol" /><pair ddi="false" e1="DDI-PubMed.30587933.s2.e0" e2="DDI-PubMed.30587933.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30587933.s2.e0" e2="DDI-PubMed.30587933.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s2.e0" e2="DDI-PubMed.30587933.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s2.e0" e2="DDI-PubMed.30587933.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30587933.s2.e0" e2="DDI-PubMed.30587933.s2.e4" /><pair ddi="false" e1="DDI-PubMed.30587933.s2.e1" e2="DDI-PubMed.30587933.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s2.e1" e2="DDI-PubMed.30587933.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s2.e1" e2="DDI-PubMed.30587933.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30587933.s2.e1" e2="DDI-PubMed.30587933.s2.e4" /><pair ddi="false" e1="DDI-PubMed.30587933.s2.e2" e2="DDI-PubMed.30587933.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s2.e2" e2="DDI-PubMed.30587933.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30587933.s2.e2" e2="DDI-PubMed.30587933.s2.e4" /><pair ddi="false" e1="DDI-PubMed.30587933.s2.e3" e2="DDI-PubMed.30587933.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30587933.s2.e3" e2="DDI-PubMed.30587933.s2.e4" /></sentence><sentence text=" Simvastatin (Svt) is a classic lipid-lowering drug that is widely used in the treatment of hypercholesterolemia and hypertriglyceridemia, while berberine chloride (Bbr) is a novel hypolipidemic agent and its blood-lipid-reducing mechanism is distinct from traditional drugs"><entity charOffset="1-12" id="DDI-PubMed.30587933.s3.e0" text="Simvastatin" /><entity charOffset="14-17" id="DDI-PubMed.30587933.s3.e1" text="Svt" /><entity charOffset="145-163" id="DDI-PubMed.30587933.s3.e2" text="berberine chloride" /><entity charOffset="165-168" id="DDI-PubMed.30587933.s3.e3" text="Bbr" /><pair ddi="false" e1="DDI-PubMed.30587933.s3.e0" e2="DDI-PubMed.30587933.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30587933.s3.e0" e2="DDI-PubMed.30587933.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s3.e0" e2="DDI-PubMed.30587933.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s3.e0" e2="DDI-PubMed.30587933.s3.e3" /><pair ddi="false" e1="DDI-PubMed.30587933.s3.e1" e2="DDI-PubMed.30587933.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s3.e1" e2="DDI-PubMed.30587933.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s3.e1" e2="DDI-PubMed.30587933.s3.e3" /><pair ddi="false" e1="DDI-PubMed.30587933.s3.e2" e2="DDI-PubMed.30587933.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s3.e2" e2="DDI-PubMed.30587933.s3.e3" /></sentence><sentence text=" Currently, drug combination is the trend in treating hyperlipidemia to improve clinical efficacy" /><sentence text=" The purpose of this study was to evaluate drug interaction from the perspective of pharmacokinetics between Bbr and Fbt/Svt and the tolerability of combined administration in healthy Chinese subjects"><entity charOffset="117-119" id="DDI-PubMed.30587933.s5.e0" text="Fbt" /><entity charOffset="121-123" id="DDI-PubMed.30587933.s5.e1" text="Svt" /><entity charOffset="109-111" id="DDI-PubMed.30587933.s5.e2" text="Bbr" /><pair ddi="false" e1="DDI-PubMed.30587933.s5.e2" e2="DDI-PubMed.30587933.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s5.e2" e2="DDI-PubMed.30587933.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30587933.s5.e2" e2="DDI-PubMed.30587933.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s5.e0" e2="DDI-PubMed.30587933.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30587933.s5.e0" e2="DDI-PubMed.30587933.s5.e1" /></sentence><sentence text="" /><sentence text="Healthy subjects (n=60) were randomly allocated to five treatment groups: Bbr alone, Fbt alone, Svt alone, Bbr plus Fbt, and Bbr plus Svt"><entity charOffset="85-87" id="DDI-PubMed.30587933.s7.e0" text="Fbt" /><entity charOffset="116-118" id="DDI-PubMed.30587933.s7.e1" text="Fbt" /><entity charOffset="96-98" id="DDI-PubMed.30587933.s7.e2" text="Svt" /><entity charOffset="134-136" id="DDI-PubMed.30587933.s7.e3" text="Svt" /><entity charOffset="74-76" id="DDI-PubMed.30587933.s7.e4" text="Bbr" /><entity charOffset="107-109" id="DDI-PubMed.30587933.s7.e5" text="Bbr" /><entity charOffset="125-127" id="DDI-PubMed.30587933.s7.e6" text="Bbr" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e4" e2="DDI-PubMed.30587933.s7.e4" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e4" e2="DDI-PubMed.30587933.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e4" e2="DDI-PubMed.30587933.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e4" e2="DDI-PubMed.30587933.s7.e5" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e4" e2="DDI-PubMed.30587933.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e4" e2="DDI-PubMed.30587933.s7.e6" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e4" e2="DDI-PubMed.30587933.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e0" e2="DDI-PubMed.30587933.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e0" e2="DDI-PubMed.30587933.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e0" e2="DDI-PubMed.30587933.s7.e5" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e0" e2="DDI-PubMed.30587933.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e0" e2="DDI-PubMed.30587933.s7.e6" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e0" e2="DDI-PubMed.30587933.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e2" e2="DDI-PubMed.30587933.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e2" e2="DDI-PubMed.30587933.s7.e5" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e2" e2="DDI-PubMed.30587933.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e2" e2="DDI-PubMed.30587933.s7.e6" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e2" e2="DDI-PubMed.30587933.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e5" e2="DDI-PubMed.30587933.s7.e5" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e5" e2="DDI-PubMed.30587933.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e5" e2="DDI-PubMed.30587933.s7.e6" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e5" e2="DDI-PubMed.30587933.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e1" e2="DDI-PubMed.30587933.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e1" e2="DDI-PubMed.30587933.s7.e6" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e1" e2="DDI-PubMed.30587933.s7.e3" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e6" e2="DDI-PubMed.30587933.s7.e6" /><pair ddi="false" e1="DDI-PubMed.30587933.s7.e6" e2="DDI-PubMed.30587933.s7.e3" /></sentence><sentence text=" The experiment was divided into two parts: single-dose administration and multiple-dose administration" /><sentence text=" Bbr, Fbt, and Svt were taken once every 8 hours, 24 hours, and 24 hours, respectively, over 7 days in the multidose group"><entity charOffset="6-8" id="DDI-PubMed.30587933.s9.e0" text="Fbt" /><entity charOffset="15-17" id="DDI-PubMed.30587933.s9.e1" text="Svt" /><entity charOffset="1-3" id="DDI-PubMed.30587933.s9.e2" text="Bbr" /><pair ddi="false" e1="DDI-PubMed.30587933.s9.e2" e2="DDI-PubMed.30587933.s9.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s9.e2" e2="DDI-PubMed.30587933.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30587933.s9.e2" e2="DDI-PubMed.30587933.s9.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s9.e0" e2="DDI-PubMed.30587933.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30587933.s9.e0" e2="DDI-PubMed.30587933.s9.e1" /></sentence><sentence text=" Plasma samples were collected and liquid chromatography-mass spectrometry/mass spectrometry was used to detect drug concentrations" /><sentence text="" /><sentence text="No serious adverse reactions or intolerance were observed throughout the trial" /><sentence text=" More importantly, the combined-administration groups did not show an increase in incidence of side effects" /><sentence text=" Coadministration of Fbt and Svt with Bbr had no significant effect on the pharmacokinetic parameters of Bbr, except time to maximum concentration, apparent volume of distribution, and apparent clearance"><entity charOffset="21-23" id="DDI-PubMed.30587933.s14.e0" text="Fbt" /><entity charOffset="29-31" id="DDI-PubMed.30587933.s14.e1" text="Svt" /><entity charOffset="38-40" id="DDI-PubMed.30587933.s14.e2" text="Bbr" /><entity charOffset="105-107" id="DDI-PubMed.30587933.s14.e3" text="Bbr" /><pair ddi="false" e1="DDI-PubMed.30587933.s14.e0" e2="DDI-PubMed.30587933.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30587933.s14.e0" e2="DDI-PubMed.30587933.s14.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s14.e0" e2="DDI-PubMed.30587933.s14.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s14.e0" e2="DDI-PubMed.30587933.s14.e3" /><pair ddi="false" e1="DDI-PubMed.30587933.s14.e1" e2="DDI-PubMed.30587933.s14.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s14.e1" e2="DDI-PubMed.30587933.s14.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s14.e1" e2="DDI-PubMed.30587933.s14.e3" /><pair ddi="false" e1="DDI-PubMed.30587933.s14.e2" e2="DDI-PubMed.30587933.s14.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s14.e2" e2="DDI-PubMed.30587933.s14.e3" /></sentence><sentence text=" Concurrent coadministration of Bbr had no obvious impact on the pharmacokinetic behavior of Fbt or Svt"><entity charOffset="93-95" id="DDI-PubMed.30587933.s15.e0" text="Fbt" /><entity charOffset="100-102" id="DDI-PubMed.30587933.s15.e1" text="Svt" /><entity charOffset="32-34" id="DDI-PubMed.30587933.s15.e2" text="Bbr" /><pair ddi="false" e1="DDI-PubMed.30587933.s15.e2" e2="DDI-PubMed.30587933.s15.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s15.e2" e2="DDI-PubMed.30587933.s15.e0" /><pair ddi="false" e1="DDI-PubMed.30587933.s15.e2" e2="DDI-PubMed.30587933.s15.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s15.e0" e2="DDI-PubMed.30587933.s15.e0" /><pair ddi="false" e1="DDI-PubMed.30587933.s15.e0" e2="DDI-PubMed.30587933.s15.e1" /></sentence><sentence text=" Additionally, there was no significant correlation between sex and pharmacokinetic results" /><sentence text="" /><sentence text="All treatments were well tolerated" /><sentence text=" No clinically obvious pharmacokinetic interactions between Bbr and Fbt/Svt were observed with combined administration"><entity charOffset="68-70" id="DDI-PubMed.30587933.s19.e0" text="Fbt" /><entity charOffset="72-74" id="DDI-PubMed.30587933.s19.e1" text="Svt" /><entity charOffset="60-62" id="DDI-PubMed.30587933.s19.e2" text="Bbr" /><pair ddi="false" e1="DDI-PubMed.30587933.s19.e2" e2="DDI-PubMed.30587933.s19.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s19.e2" e2="DDI-PubMed.30587933.s19.e0" /><pair ddi="false" e1="DDI-PubMed.30587933.s19.e2" e2="DDI-PubMed.30587933.s19.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s19.e0" e2="DDI-PubMed.30587933.s19.e0" /><pair ddi="false" e1="DDI-PubMed.30587933.s19.e0" e2="DDI-PubMed.30587933.s19.e1" /></sentence><sentence text=" The results demonstrated that Bbr can be coadministered safely with Fbt and Svt without dose adjustment"><entity charOffset="69-71" id="DDI-PubMed.30587933.s20.e0" text="Fbt" /><entity charOffset="77-79" id="DDI-PubMed.30587933.s20.e1" text="Svt" /><entity charOffset="31-33" id="DDI-PubMed.30587933.s20.e2" text="Bbr" /><pair ddi="false" e1="DDI-PubMed.30587933.s20.e2" e2="DDI-PubMed.30587933.s20.e2" /><pair ddi="false" e1="DDI-PubMed.30587933.s20.e2" e2="DDI-PubMed.30587933.s20.e0" /><pair ddi="false" e1="DDI-PubMed.30587933.s20.e2" e2="DDI-PubMed.30587933.s20.e1" /><pair ddi="false" e1="DDI-PubMed.30587933.s20.e0" e2="DDI-PubMed.30587933.s20.e0" /><pair ddi="false" e1="DDI-PubMed.30587933.s20.e0" e2="DDI-PubMed.30587933.s20.e1" /></sentence><sentence text="" /></document>